This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes (COMET)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2014 by Laboratorios Silanes S.A. de C.V..
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Laboratorios Silanes S.A. de C.V. Identifier:
First received: June 29, 2011
Last updated: February 19, 2014
Last verified: February 2014
The aim of this study is to compare the efficacy and safety of Metformin Glycinate versus Metformin Hydrochloride in metabolic control and inflammatory mediators in Mexican drug naïve type 2 diabetes patients, in a 12 months follow up.

Condition Intervention Phase
Type 2 Diabetes Drug: Metformin glycinate Drug: Metformin hydrochloride Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients

Resource links provided by NLM:

Further study details as provided by Laboratorios Silanes S.A. de C.V.:

Primary Outcome Measures:
  • Glycosylated hemoglobin (HbA1c) [ Time Frame: 12 months ]

    HbA1c: Measured by electrophoresis of lacked total blood using Paragon system and Appraise reader 44800 (Beckman Instruments de Mexico).

    Fasting Glucose: in serum using glucose oxidase technique with BM/Hitachi 704/911 automated analyzer

Secondary Outcome Measures:
  • Fasting glucose [ Time Frame: 12 months ]
  • Total cholesterol [ Time Frame: 12 months ]
  • High-density lipoprotein (HDL) [ Time Frame: 12 months ]
  • Low-density lipoprotein (LDL) [ Time Frame: 12 months ]
  • Triglycerides [ Time Frame: 12 months ]
  • Tumor necrosis factor-alpha (TNF-α) [ Time Frame: 12 months ]
  • Adiponectin [ Time Frame: 12 months ]
  • Resistin [ Time Frame: 12 months ]
  • Interleukin-1 beta (IL-1β) [ Time Frame: 12 months ]
  • Number of Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 12 months ]
  • Malonylaldehyde [ Time Frame: 12 months ]
  • Dismutase superoxide [ Time Frame: 12 months ]

Estimated Enrollment: 200
Study Start Date: August 2011
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metformin glycinate Drug: Metformin glycinate
Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
Active Comparator: Metformin Hydrochloride Drug: Metformin hydrochloride
12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes according ADA
  • Less than a year of evolution since diagnosis
  • Antihyperglycemic pharmacological treatment
  • HbA1c between 7.1% and 9.0%
  • Stable weight during the last 6 months
  • Body Mass Index ≥ 25 kg/m2 and <35kg/m2.
  • Blood pressure ≤ 130/80 mmHg
  • Childbearing women under contraceptive treatment
  • Signed Informed Consent Form
  • Age from 18 to 70 years old

Exclusion Criteria:

  • Non-fulfilment treatment in the screening period
  • Drugs or alcohol abuse
  • Creatinine depuration estimated with MDRD formula using serum creatinine < 90 ml/min/1.72m2
  • History of chronic liver disease, ALT or AST ≥ 2 times from the normal superior limit, or GGT ≥ 3 times from the normal superior limit.
  • Chronic lung disease, that causes dyspnea equivalent to a functional class ≥3 (NYHA)or that requires oxygen supplementation.
  • History or symptoms of coronary artery disease (CAD) or cerebrovascular disease (CVD).
  • Drug treatment that interact with biguanides.
  • Another chronic diseases that restricts survival or associated with chronic inflammation like: cancer, leukemia, lymphoma, erythematosus lupus, asthma, rheumatoid arthritis or infection for HIV.
  • Pregnancy or positive pregnancy test in women under 50 years old or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01386671

Unidad de Investigacion en Epidemiologia Clinica. UMAE Hospital de Especialidades Centro Medico Nacional Siglo XXI. Instituto Mexicano del Seguro Social
Col. Doctores, Distrito Federal, Mexico, 06720
Sponsors and Collaborators
Laboratorios Silanes S.A. de C.V.
Principal Investigator: Niels H Wacher, PhD IMSS
  More Information


Responsible Party: Laboratorios Silanes S.A. de C.V. Identifier: NCT01386671     History of Changes
Other Study ID Numbers: GlyMet01_13062011
Study First Received: June 29, 2011
Last Updated: February 19, 2014

Keywords provided by Laboratorios Silanes S.A. de C.V.:
Type 2 Diabetes
metformin glycinate
metabolic control

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017